BMS prevails in antitrust lawsuit over its defense of multiple myeloma blockbuster Pomalyst

A New York City federal court has dismissed a proposed class action lawsuit against Bristol Myers Squibb that accused the drugmaker of deploying anticompetitive tactics to protect the market exclusivity of key multiple myeloma drug Pomalyst.